Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Oncology

Long-term Monitoring and Men's Health

At a Glance

After treating testicular seminoma, long-term surveillance is vital to catch relapses and manage late-term side effects. A typical 5-year roadmap includes regular CT or MRI scans and blood work. Doctors will also monitor your testosterone levels and cardiovascular health.

Surviving testicular seminoma is a major victory, but it marks the beginning of a new phase: proactive survivorship. Because this cancer is so curable, you may live for many decades after treatment. Your focus now shifts to “watching the gate” through regular monitoring and managing your long-term physical and hormonal health [1][2].

The Five-Year Roadmap

The goal of surveillance is to catch a potential relapse as early as possible while minimizing your exposure to unnecessary radiation from scans [3]. While schedules vary by hospital, a typical NCCN (National Comprehensive Cancer Network) surveillance path for Stage I seminoma often looks like this [4][5]:

  • Years 1–2: Abdominal CT or MRI scans every 6 to 12 months, along with physical exams and blood work [4][6].
  • Years 3–5: Scans and exams become less frequent, typically every 12 to 24 months [4].
  • Beyond Year 5: Most relapses occur within the first two years, but “late relapses” (after 5 years) are possible, so occasional follow-ups may continue [7][2].

In pure seminoma, imaging (CT/MRI) is the primary tool for detection because blood markers like hCG and LDH only show elevation in a small number of patients [8][9].

Managing “Scanxiety”

It is completely normal to feel a spike in stress in the days or weeks leading up to a follow-up appointment—a phenomenon known as scanxiety [10][11]. To manage this, many patients find it helpful to:

  • Schedule scans for earlier in the week to avoid waiting over a weekend for results [11].
  • Request a clear timeline from the doctor on exactly when and how results will be shared [12][13].
  • Practice mindfulness or present-moment focus techniques to stay grounded during the wait [14].

Hormonal Health and Testosterone

Removing one testicle and undergoing additional treatments can impact your hormone production. The remaining testicle often compensates, but it may not always produce enough testosterone for optimal health [15][16]. Your doctor should check your baseline testosterone level before surgery, or shortly after, and then monitor it regularly during your follow-up appointments [17].

Hypogonadism (low testosterone) can lead to fatigue, depressed mood, weight gain, and sexual dysfunction (including low libido or erectile issues) [18][19]. Regular monitoring of your testosterone levels is essential to ensure your quality of life remains high [17][20].

Long-Term Health Risks

Depending on your treatment, you should work with your doctor to monitor for specific late-term side effects [21][22]:

  • Cardiovascular Health: Both radiation and cisplatin-based chemotherapy (like BEP) can increase the risk of heart disease, high blood pressure, or metabolic changes over time [23][24][25].
  • Secondary Malignancies: There is a slightly increased risk of developing a second, different cancer decades after treatment with radiation or chemotherapy [26][27].

Being a proactive survivor means staying vigilant with your follow-ups while also leading a heart-healthy lifestyle. Your care team is there to help you not just stay cancer-free, but stay healthy for the long term.

Common questions in this guide

What is the typical follow-up schedule after seminoma treatment?
For the first two years, surveillance usually involves physical exams, blood work, and abdominal CT or MRI scans every 6 to 12 months. In years three through five, scans and exams become less frequent, typically occurring every 12 to 24 months.
Why do I need CT or MRI scans instead of just blood tests?
In pure seminoma, blood markers like hCG and LDH only show elevation in a small number of patients. Therefore, imaging like CT or MRI scans is the primary and most reliable tool for detecting a potential relapse early.
Will I have low testosterone after losing a testicle?
While your remaining testicle often compensates to produce enough testosterone, it may not always be sufficient. Your doctor should monitor your testosterone levels during follow-up visits to check for hypogonadism, which can cause fatigue, mood changes, and sexual dysfunction.
What are the long-term health risks of seminoma treatment?
Treatments like radiation and cisplatin-based chemotherapy can increase the risk of late-term side effects such as heart disease, high blood pressure, and metabolic changes. There is also a slightly increased risk of developing a secondary cancer decades after treatment.
How can I manage anxiety before my follow-up scans?
'Scanxiety' is a common and normal reaction before follow-up appointments. You can manage it by scheduling scans early in the week to avoid weekend waits, establishing a clear timeline for results with your doctor, and practicing mindfulness.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific timeline for my scans and blood work over the next five years?
  2. 2.When should we check my first post-treatment testosterone level, and what was my baseline before surgery?
  3. 3.Based on the treatment I received (surgery, radiation, or chemo), what are my specific long-term risks for heart health or secondary cancers?
  4. 4.If I notice new fatigue or sexual dysfunction, should I contact you or my primary care doctor first?
  5. 5.Can we schedule a 'results' call or appointment as close to my scan date as possible to minimize waiting?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (27)
  1. 1

    Management of Low-Stage Testicular Seminoma.

    Pearce SM, Liauw SL, Eggener SE

    The Urologic clinics of North America 2015; (42(3)):287-98.

    PMID: 26216816
  2. 2

    Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors.

    Gariscsak PJ, Anson-Cartwright L, Atenafu EG, et al.

    European urology open science 2022; (40()):46-53 doi:10.1016/j.euros.2022.03.010.

    PMID: 35638085
  3. 3

    The role of diagnostic imaging in the primary testicular cancer: initial staging, response assessment and surveillance.

    Thomas KL, Jeong D, Montilla-Soler J, Feuerlein S

    Translational andrology and urology 2020; (9(Suppl 1)):S3-S13 doi:10.21037/tau.2019.07.01.

    PMID: 32055480
  4. 4

    First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).

    Fischer S, Gillessen S, Stalder O, et al.

    European urology open science 2024; (68()):68-74 doi:10.1016/j.euros.2024.08.008.

    PMID: 39308640
  5. 5

    French AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer.

    Murez T, Fléchon A, Branger N, et al.

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 2022; (32(15)):1066-1101 doi:10.1016/j.purol.2022.09.009.

    PMID: 36400478
  6. 6

    No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer.

    De La Pena H, Sharma A, Glicksman C, et al.

    European journal of cancer (Oxford, England : 1990) 2017; (84()):354-359 doi:10.1016/j.ejca.2017.07.005.

    PMID: 28866371
  7. 7

    Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.

    Fischer S, Tandstad T, Wheater M, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(2)):194-200 doi:10.1200/JCO.2016.69.0958.

    PMID: 27893332
  8. 8

    Testicular Cancer, Version 2.2015.

    Motzer RJ, Jonasch E, Agarwal N, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2015; (13(6)):772-99 doi:10.6004/jnccn.2015.0092.

    PMID: 26085393
  9. 9

    Non-Coding microRNAs as Novel Potential Tumor Markers in Testicular Cancer.

    Regouc M, Belge G, Lorch A, et al.

    Cancers 2020; (12(3)) doi:10.3390/cancers12030749.

    PMID: 32235691
  10. 10

    Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey.

    Bui KT, Kiely BE, Dhillon HM, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(1)):511-519 doi:10.1007/s00520-021-06454-9.

    PMID: 34333717
  11. 11

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  12. 12

    The experience of patients participating in a small randomised control trial that explored two different interventions to reduce anxiety prior to an MRI scan.

    Tugwell-Allsup J, Pritchard AW

    Radiography (London, England : 1995) 2018; (24(2)):130-136 doi:10.1016/j.radi.2017.11.001.

    PMID: 29605109
  13. 13

    Scan-Associated Distress in People Affected by Cancer: A Qualitative Systematic Review.

    Hussain M, Chau S, Turner M, Paterson C

    Seminars in oncology nursing 2023; (39(5)):151502 doi:10.1016/j.soncn.2023.151502.

    PMID: 37735038
  14. 14

    Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

    Dunsmore VJ, Neupert SD

    Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

    PMID: 36964680
  15. 15

    Association between low total serum testosterone and body mass index in Australian survivors of testicular cancer: a retrospective analysis.

    Kim GY, Conduit C, O'Haire S, et al.

    Basic and clinical andrology 2024; (34(1)):14 doi:10.1186/s12610-024-00230-5.

    PMID: 39223491
  16. 16

    High risk of hypogonadism in young male cancer survivors.

    Isaksson S, Bogefors K, Ståhl O, et al.

    Clinical endocrinology 2018; (88(3)):432-441 doi:10.1111/cen.13534.

    PMID: 29245176
  17. 17

    Biochemical Hypogonadism in Aging Testicular Cancer Survivors: A Clinical Challenge.

    Fosså SD, Bjerner LJ, Tandstad T, et al.

    European urology open science 2025; (72()):10-16 doi:10.1016/j.euros.2024.12.010.

    PMID: 39897186
  18. 18

    Erectile dysfunction among testicular cancer survivors: A systematic review and meta-analysis.

    Kerie S, Workineh Y, Kasa AS, et al.

    Heliyon 2021; (7(7)):e07479 doi:10.1016/j.heliyon.2021.e07479.

    PMID: 34286139
  19. 19

    Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome.

    Bogefors C, Isaksson S, Bobjer J, et al.

    Andrology 2017; (5(4)):711-717 doi:10.1111/andr.12354.

    PMID: 28544654
  20. 20

    Key Updates in Testicular Cancer: Optimizing Survivorship and Survival.

    Bagrodia A, Haugnes HS, Hellesnes R, et al.

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2025; (45(3)):e472654 doi:10.1200/EDBK-25-472654.

    PMID: 40324110
  21. 21

    Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life.

    Lubberts S, Groot HJ, de Wit R, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(19)):3512-3522 doi:10.1200/JCO.22.01016.

    PMID: 37071834
  22. 22

    Cardiovascular toxicity in testicular germ cell tumor survivors.

    Orszaghova Z, Mladosievicova B, Mego M, Chovanec M

    Frontiers in oncology 2025; (15()):1654063 doi:10.3389/fonc.2025.1654063.

    PMID: 40881865
  23. 23

    Treatment-related Cardiovascular Toxicity in Long-term Survivors of Testicular Cancer.

    Gugic J, Zaletel LZ, Oblak I

    Radiology and oncology 2017; (51(2)):221-227 doi:10.1515/raon-2016-0021.

    PMID: 28740458
  24. 24

    Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy.

    Stelwagen J, Lubberts S, Steggink LC, et al.

    British journal of cancer 2020; (123(11)):1599-1607 doi:10.1038/s41416-020-01049-3.

    PMID: 32921790
  25. 25

    Associations of Body Fat Distribution and Cardiometabolic Risk of Testicular Cancer Survivors After Cisplatin-Based Chemotherapy.

    Wibmer AG, Dinh PC, Travis LB, et al.

    JNCI cancer spectrum 2022; (6(4)) doi:10.1093/jncics/pkac030.

    PMID: 35801305
  26. 26

    Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort.

    Hellesnes R, Myklebust TÅ, Fosså SD, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(32)):3561-3573 doi:10.1200/JCO.21.00637.

    PMID: 34388002
  27. 27

    Prevalence of neoplasia at colonoscopy among testicular cancer survivors treated with platinum-based chemotherapy.

    Breekveldt ECH, Ykema BLM, Bisseling TM, et al.

    International journal of cancer 2024; (154(8)):1474-1483 doi:10.1002/ijc.34810.

    PMID: 38151749

This page provides educational information about survivorship and long-term monitoring for testicular seminoma. Always consult your oncology team for your specific surveillance schedule and health concerns.

Get notified when new evidence is published on Testicular seminomatous germ cell tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.